Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update
Sambuddha Ghosh, Lusine Breitscheidel, Natasa Lazarevic, Alexandra Martin, Jeffrey Hafkin, Norbert Hittel
Source: Eur Respir J, 57 (5) 2002483; 10.1183/13993003.02483-2020
Abstract
Background
Although delamanid has been approved for the treatment of multidrug-resistant TB (MDR-TB) in numerous regions, in areas where it is not yet registered it can be accessed as part of salvage therapy (in particular for those patients with limited treatment options) via the Otsuka compassionate use programme. Here we present the analysis of interim treatment outcomes by 24 weeks of more than 200 MDR-TB patients globally who received delamanid under this programme.
Methods
We evaluated treatment efficacy with respect to culture negativity at 24 weeks, as well as the safety profile of delamanid, in an MDR-TB patient cohort treated under compassionate use between 2014 and 2019.
Results
Among patients who received delamanid as part of a multidrug regimen, 123 (61%) out of 202 had extensively drug-resistant TB (XDR-TB), 66 (33%) out of 202 had HIV co-infection and 34 (17%) out of 202 were children aged between 6 and 17 years. Of those patients who were culture positive at delamanid treatment initiation and who completed 24 weeks of delamanid treatment in combination with other anti-tuberculosis (TB) drugs, culture negativity was achieved in 116 (79%) out of 147 cases. The corresponding rates of culture negativity for patients with XDR-TB and HIV co-infection, as well as the paediatric subgroup were 69 (77%) out of 90, 44 (92%) out of 48 and 20 (80%) out of 25, respectively. QT interval prolongation was the most frequently observed serious adverse event and was reported in 8% of patients receiving delamanid. Overall, treatment safety outcomes did not reveal any new or unidentified risks.
Conclusions
The use of delamanid combined with other active drugs has the potential to achieve high rates of culture negativity in difficult-to-treat drug-resistant TB cases, with a favourable safety profile.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sambuddha Ghosh, Lusine Breitscheidel, Natasa Lazarevic, Alexandra Martin, Jeffrey Hafkin, Norbert Hittel. Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J, 57 (5) 2002483; 10.1183/13993003.02483-2020
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Effectiveness of treatment for MDR TB in children and adolescents Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges Source: Eur Respir J 2016; 48: 938-943 Year: 2016
ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use Source: Eur Respir J 2014; 44: 811-815 Year: 2014
Bedaquiline in the treatment of multidrug-resistant tuberculosis: a subanalysis in Korean population Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Preventive chemotherapy effectiveness in children and adolescents, contacting TB patients with DR TB strains Source: Eur Respir J 2006; 28: Suppl. 50, 536s Year: 2006
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Patients over 35 years experience more side-effects during latent TB treatment: Experience from an urban hospital with a high incidence of Tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Incidence of tuberculosis among anti-TNF users in patients with previous history of tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Predictors of defaulting from treatment among patients with tuberculosis Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review Source: Eur Respir J, 52 (1) 1800395; 10.1183/13993003.00395-2018 Year: 2018
Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018 Year: 2019
A two-year post-treatment follow-up of multi-drug resistant tuberculosis cases who completed a programmatic MDR-TB management at the lung center of the Philippines – a preliminary report Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009